CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Catalyst Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Catalyst Pharmaceuticals Inc
355 ALHAMBRA CIRCLE, SUITE 801
Phone: (305) 529-2522p:305 529-2522 CORAL GABLES, FL  33134  United States Ticker: CPRXCPRX
On 12/23/2016, Catalyst Pharmaceuticals Inc filed a Registration Withdrawal Request of its Form S-3 (File No. 333-193699) with the SEC. The Post-Effective Amendment is being withdrawn at the request of the SEC and will be replaced by the filing of a new registration statement. The Post-EffectiveAmendment has not been declared effective and none of the Company's securities has been sold pursuant to the Post-Effective Amendment.
Business Summary
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Patrick J.McEnany 75 12/31/2023 1/1/2002
Chief Executive Officer, Director Richard J.Daly 62 1/1/2024 2/19/2015
Chief Financial Officer, Executive Vice President Michael W.Kalb 53 1/1/2024 1/1/2024
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Catalyst Pharamaceuticals Ireland, Ltd.
Catalyst Pharmaceutical Partners, Inc.
CPRX

General Information
Number of Employees: 167 (As of 2/28/2024)
Outstanding Shares: 118,011,092 (As of 3/28/2024)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 760837053
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024